Summary
- Authoritative Selection: Johnson & Johnson (
JNJ) is selected as the sole current S&P 500 pick (verified constituent as of2026-11-20 10:23:07 ESTen.wikipedia.S&P 500 constituent snapshotMembership fetched at 2026-11-20T15:23:07.555050+00:00Visit original website ↗finance.yahooYahoo Finance screener: sp500Universe=sp500Visit original website ↗) for the 7-calendar-day holding horizon (2026-11-20 10:20:01 ESTto2026-11-27 10:20:01 EST, approximately4.0regular-session equivalents due to the Thanksgiving Day closure on November 26 and the1:00 PM ESTearly close on November 27 nyseHolidays & Trading HoursAll NYSE markets observe U.S. holidays as listed below for 2026, Thanksgiving Day Thursday, November. Each market will close early at 1:00 p.m. (1:15 p.m. for ...Visit original website ↗nyseHolidays & Trading HoursICE NYSE LOGIN Listings Trading Market Data Insights About Trading at NYSE / Holidays & Trading Hours Holidays & Trading Hours All NYSE markets observe U.S. holidays as listed below for 2026, 2027, and 2028. Trading Days Trading Hours Holiday 2026 2027 2028 New Year’s Day Thursday, January 1 Friday, January 1 —* Martin Luther King, Jr. Day Monday, January 19 Monday, January 18 Monday, January 17 Washington's…Visit original website ↗). - Fresh Publication Quote Check: The latest market quote for
JNJis$271.075observed at2026-11-20 11:21:00 EST(retrieved11:21:02 EST,+1.47%vs. prior close$267.140finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗), drifting just+0.05%above the decider's authored research entry of$270.935(2026-11-20 11:10:00 ESTfinance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗) and leaving structural support at$263.50completely unbroken. - Decider Forecast & Ranking Edge: Under the decider's uncalibrated analyst estimates referenced to
$270.935,JNJpasses the pre-uncertainty absolute-return gate with+1.1609%expected net return (+0.4609%base excess vs. the decider's+0.70%7-daySPYbenchmark estimate), ranking #1 across all 10 reviewed S&P 500 finalists on uncertainty-adjusted excess return (-1.6391%after a2.10 ppuncertainty deduction), Expected R (+0.4230), profit-to-stop probability headroom (10.29 pp), and coherent adverse-market stress excess return (+0.3103%vs.-1.18%stressedSPY). - Catalyst & Income Cushion:
JNJcombines four fresh November 17–20 clinical and commercial milestones—Phase 4 STAR TREMFYA data prnewswireJohnson & Johnson data in psoriatic arthritis (PsA) shows ...NEW BRUNSWICK, N.J., Nov. 20, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced late-breaking results from the Phase 4 STAR study of TREMFYA ( ...Visit original website ↗, CAPLYTA bipolar mania FDA sNDA jnjJohnson & Johnson Seeks U.S. FDA Approval for ...Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication. · Two positive Phase 3 studies showed CAPLYTA ...Visit original website ↗, first commercial OTTAVA robotic surgical system installation quantisnowJohnson & Johnson Announces First Commercial ...Nov 16, 2026, Johnson & Johnson to acquire Ollin ... JNJ dividend history Dividends Johnson & Johnson has declared, with ex-dates and payment dates.Visit original website ↗, and RYBREVANT FASPRO FDA accelerated approval patientworthyFDA Approves RYBREVANT FASPRO for Some Adults ...As shared in a recent press statement by Johnson & Johnson, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to RYBREVANT FASPRO ...Visit original website ↗—with a confirmed$1.34/share(+0.495%) Q4 ex-dividend on Tuesday, November 24, 2026 investor.jnjJohnson & Johnson Announces Quarterly Dividend for Fourth ...Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026 ... The ex-dividend date is November 24, 2026. About Johnson & Johnson.Visit original website ↗ and zero pending company-specific binary events inside the November 20–27 window. - Confidence Rationale (
Medium, descriptive only): Low-beta (0.20) defensive leadership finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗, deep liquidity ($2.07B20-day average daily dollar volume finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗), and positive stressed excess return support aMediumconfidence label, tempered by uncalibrated exit probabilities, elevated Thanksgiving-week macro dispersion, the mechanical November 24 ex-dividend price drop narrowing the stop buffer, and ongoing talc/FDA marketing headline overhang.
Why Now
Recent Developments (November 16–20, 2026): Johnson & Johnson enters the Thanksgiving-shortened week with a dense cluster of objective pipeline and MedTech execution milestones:
- November 20, 2026: Late-breaking Phase 4 STAR study data showed TREMFYA (guselkumab) is the only advanced therapy demonstrating MRI-confirmed improvements in spinal pain and stiffness in psoriatic arthritis prnewswireJohnson & Johnson data in psoriatic arthritis (PsA) shows ...NEW BRUNSWICK, N.J., Nov. 20, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced late-breaking results from the Phase 4 STAR study of TREMFYA ( ...Visit original website ↗.
- November 19, 2026: JNJ submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for CAPLYTA in bipolar mania (its fifth potential indication) jnjJohnson & Johnson Seeks U.S. FDA Approval for ...Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication. · Two positive Phase 3 studies showed CAPLYTA ...Visit original website ↗ and announced the first commercial installation of its OTTAVA robotic surgical system at Memorial Hermann quantisnowJohnson & Johnson Announces First Commercial ...Nov 16, 2026, Johnson & Johnson to acquire Ollin ... JNJ dividend history Dividends Johnson & Johnson has declared, with ex-dates and payment dates.Visit original website ↗xtenet researchJNJ Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System.Visit original website ↗.
- November 17–18, 2026: The FDA granted accelerated approval for RYBREVANT FASPRO patientworthyFDA Approves RYBREVANT FASPRO for Some Adults ...As shared in a recent press statement by Johnson & Johnson, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to RYBREVANT FASPRO ...Visit original website ↗, following Monday November 16's sweeping
$5.5Btalc settlement framework ddnews.gov.iJ&J reaches sweeping talc deal that could end decade ...Johnson & Johnson said on Monday it would pay an estimated $5.5 billion to resolve tens of thousands of lawsuits alleging its baby powder and other talc ...Visit original website ↗ and a$750MBlackstone Life Sciences Phase 3 collaboration xBlackstoneWe're pleased to expand our relationship with Johnson & Johnson through a $750 million agreement for Blackstone Life Sciences to support the Phase 3 ...Visit original website ↗. - Confirmed Near-Term Income: JNJ goes ex-dividend on Tuesday, November 24, 2026 for its Q4 quarterly dividend of
$1.34/share(+0.495%at$270.935, payable December 8) investor.jnjJohnson & Johnson Announces Quarterly Dividend for Fourth ...Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026 ... The ex-dividend date is November 24, 2026. About Johnson & Johnson.Visit original website ↗marketchamelJohnson & Johnson sets $1.34 quarterly dividend with ...Johnson & Johnson's board declared a $1.34 per share cash dividend for the fourth quarter of 2026. The company set November 24, 2026 as the ...Visit original website ↗.
Why Actionable Now vs. Rejected Finalists: None of the November 17–20 clinical or MedTech milestones creates an immediate 7-day EPS step-change; rather, they reinforce defensive institutional rotation into Healthcare while SPY trades -1.21% intraday ($707.190 at 11:10:00 EST) below its $711.486 session VWAP and $730.199 200-day moving average amid AI/semiconductor unwinding finance.yahoYahoo Finance: State Street SPDR S&P 500 ETF TrustYahoo Finance quote pageVisit original website ↗. Over the last 20 completed sessions through November 19, JNJ gained +1.26% versus -5.80% for SPY (+7.06 pp relative outperformance) and -1.02% for XLV (+2.28 pp sector alpha) finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗. After pulling back -2.15% on November 18 and -2.04% on November 19 to test $264.680, JNJ rebounded +1.42% to $270.935 at 11:10:00 EST (+2.63 pp intraday alpha vs. SPY) without triggering any post-catalyst over-extension gate finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗.
Compared with the next best viable finalists under the decider's synchronized forecast model:
- vs. Procter & Gamble (
PG, Rank #2):JNJdelivers higher base expected net return (+1.1609%vs.+0.8810%), higher uncertainty-adjusted excess return (-1.6391%vs.-1.8190%), higher Expected R (+0.4230vs.+0.2827), and higher stressedSPYexcess (+0.3103%vs.+0.1652%).PG's November 19 Investor Day left FY27 guidance unchanged rttnewsP&G Plans To Cut Up To 30% Jobs By 2030In its Investor Day on Thursday, the firm also maintained fiscal 2027 forecast for net sales growth of 2 to 4 percent and organic sales growth of 1 to 3 percent ...Visit original website ↗ and addingPGwould severely overcrowd the portfolio's existing25.36%Consumer Defensive weight (COST,TGT,WMT). - vs. Casey's General Stores (
CASY, Rank #3):CASYoffers cleaner Consumer Cyclical portfolio fit (8.29%weight) and virtually tied base expected return (+1.1444%), but relies on a November 17 Stifel Buy initiation ($800PT marketbeatStifel Nicolaus Begins Coverage on Casey's General ...Stifel Nicolaus initiated coverage of Casey's General Stores with a “buy” rating and an $800 price target, implying 13.36% upside from the prior close. Analyst ...Visit original website ↗) rather than an issuer release, faces a declining$745.643200-day moving average directly beneath its$760.521.8×profit barrier, carries Stifel-flagged Q1 fuel-margin peak risk barronsHow to Invest Around Consumer Resilience: Video... Casey's General Stores after a post-earnings drop. Teresa Rivas explained that prolonged high fuel prices limit fuel margin arbitrage and reduce store ...Visit original website ↗, and turns negative in stressedSPYexcess (-0.1869%vs.JNJ +0.3103%). - vs. Lowe's (
LOW, Rank #4), Erie Indemnity (ERIE, Rank #5), and Rollins (ROL, Rank #6):LOWcarries wider3.15 ppuncertainty and negative stressed excess (-0.5399%) due to a one-time$0.34tariff refund embedded in Q3 EPS and a10 bpsFY26 margin trim;ERIElacks a fresh catalyst and suffers thin intraday liquidity ($56.2MADV);ROLcarries the widest uncertainty deduction (3.80 pp) among the top six finalists with no fresh November 18–20 catalyst and a3.52× ATR14distance to its1.8×profit barrier.
Business And Market Context
Johnson & Johnson operates across two global healthcare segments—Innovative Medicine (oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular/metabolism) and MedTech (surgery, orthopedics, cardiovascular, and vision, including robotic surgical platforms such as OTTAVA) finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗. With a $652.6B market capitalization, 2.01% dividend yield, and 0.20 beta finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗, JNJ functions as a core institutional defensive anchor during equity drawdowns.
The broad market backdrop on November 20 is a bifurcated risk-off tape rather than a confirmed broad-market crash: SPY ($707.190 at 11:10:00 EST) is down -1.21% intraday below its 200-day moving average ($730.199) as AI and semiconductor leaders unwind, while defensive healthcare and staples attract relative inflows finance.yahoYahoo Finance: State Street SPDR S&P 500 ETF TrustYahoo Finance quote pageVisit original website ↗. Macro event risk is concentrated inside the shortened Thanksgiving week:
- Fri Nov 20 (
12:15 PM EST): Fed Gov. Cook remarks federalreserFederal Reserve Board - Calendar: November 2026FOMC Meetings. Time: Release Date(s):. 2:00 p.m.. FOMC Minutes. Meeting of October 27-28. 18. Beige Book. Time: Release Date(s):. 2:00 p.m..Visit original website ↗. - Mon Nov 23 (
9:45 AM EST): S&P Global U.S. Flash PMI pmi.spglobalPMI by S&P Global release calendarS&P Global PMI release dates: October / November 2026. Local time zone ... Flash PMI (Manufacturing, Services, Composite). Australia. PMI\AU\COM\OB\F. 15 ...Visit original website ↗. - Tue Nov 24 (
10:00 AM EST): Conference Board Consumer Confidence conference-bsourceVisit original website ↗. - Wed Nov 25 (
8:30 AM ESTcluster): Q3 GDP (2nd Estimate) & October PCE/Core PCE bea.govRelease Schedule | U.S. Bureau of Economic Analysis (BEA)Release Schedule Upcoming Releases Full Schedule 2025 Schedule 2027 Schedule N ews Release D ata Release VVisit original website ↗, Advance Durable Goods census.govsourceVisit original website ↗, and Weekly Jobless Claims oui.doleta.gOffice of Unemployment InsurancePrior versions of the News Release are available through the application tool below. Publication Schedule: The UI Weekly Claims News Release is published each ...Visit original website ↗, followed by10:00 AM ESTNew Home Sales census.govsourceVisit original website ↗ and2:00 PM ESTBeige Book federalreserFederal Reserve Board - Calendar: November 2026FOMC Meetings. Time: Release Date(s):. 2:00 p.m.. FOMC Minutes. Meeting of October 27-28. 18. Beige Book. Time: Release Date(s):. 2:00 p.m..Visit original website ↗. - Fri Nov 27 (
8:30 AM EST): Advance International Trade & Inventories census.govsourceVisit original website ↗.
In this macro-heavy, 4-session week, JNJ's 0.20 beta and confirmed $1.34 ex-dividend cash cushion provide superior relative insulation compared with higher-beta cyclical or technology alternatives. Portfolio-wise, JNJ adds to an existing 16.63% Healthcare allocation (ALGN, REGN), which is elevated but materially less crowded than Consumer Defensive (25.36%).
Factor Stack
| Factor | Sourced Observations | Decider Assessment / Estimates |
|---|---|---|
| Catalyst / News Edge | Four Nov 17–20 milestones (TREMFYA Phase 4 prnewswireJohnson & Johnson data in psoriatic arthritis (PsA) shows ...NEW BRUNSWICK, N.J., Nov. 20, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced late-breaking results from the Phase 4 STAR study of TREMFYA ( ...Visit original website ↗, CAPLYTA sNDA jnjJohnson & Johnson Seeks U.S. FDA Approval for ...Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication. · Two positive Phase 3 studies showed CAPLYTA ...Visit original website ↗, OTTAVA first install quantisnowJohnson & Johnson Announces First Commercial ...Nov 16, 2026, Johnson & Johnson to acquire Ollin ... JNJ dividend history Dividends Johnson & Johnson has declared, with ex-dates and payment dates.Visit original website ↗, RYBREVANT FASPRO approval patientworthyFDA Approves RYBREVANT FASPRO for Some Adults ...As shared in a recent press statement by Johnson & Johnson, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to RYBREVANT FASPRO ...Visit original website ↗), Nov 16 $5.5B talc framework ddnews.gov.iJ&J reaches sweeping talc deal that could end decade ...Johnson & Johnson said on Monday it would pay an estimated $5.5 billion to resolve tens of thousands of lawsuits alleging its baby powder and other talc ...Visit original website ↗, and $1.34 Nov 24 ex-dividend investor.jnjJohnson & Johnson Announces Quarterly Dividend for Fourth ...Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026 ... The ex-dividend date is November 24, 2026. About Johnson & Johnson.Visit original website ↗. |
Strong defensive/pipeline sentiment support; zero immediate 7-day EPS step-change. |
| Growth & Profitability | Mega-cap scale ($652.6B market cap) with diversified Innovative Medicine and MedTech cash flows; 2.01% dividend yield finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗. |
No solvency or liquidity concerns; $2.07B 20D average daily dollar volume supports tight execution (0.12% estimated friction). |
| Valuation | Trailing P/E 41.13×, Forward P/E 23.34×, PEG 3.07, P/B 8.00× at $271.075 (11:21:00 EST) finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗. |
Not a deep-value discount; valuation is supported by defensive quality and pipeline durability rather than multiple expansion. |
| Momentum / Relative Strength | 20D return +1.26% vs. SPY -5.80% (+7.06 pp alpha) and XLV -1.02% (+2.28 pp alpha) through Nov 19; above SMA50 ($267.330) and SMA200 ($250.664), slightly below SMA20 ($274.676) and session VWAP ($271.638 at 11:20 EST) finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗. |
Constructive pullback-and-rebound structure; over-extension gate not triggered. |
| Sentiment / Social Confirmation | Constructive X.com commentary highlighting OTTAVA commercial installation xtenet researchJNJ Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System.Visit original website ↗, CAPLYTA sNDA xTENET RESEARCH on XJNJ - Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication.Visit original website ↗, Blackstone $750M collaboration xBlackstoneWe're pleased to expand our relationship with Johnson & Johnson through a $750 million agreement for Blackstone Life Sciences to support the Phase 3 ...Visit original website ↗, and 64-year Dividend Aristocrat safe-haven status xJohnson & Johnson $JNJ is up 49% over the past year and ...Johnson & Johnson $JNJ is up 49% over the past year and just closed at a new all-time high. That is not a tech stock. It is a 64-year Dividend Aristocrat, ...Visit original website ↗. Low short float (0.79%, 2.2 days to cover) finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗. |
Supportive institutional/retail defensive narrative; tempered by Nov 19 FDA Inlexzo marketing rebuke fiercepharmaJ&J draws FDA rebuke over Inlexzo bladder-sparing ...The FDA slammed J&J over misleading claims about its bladder cancer drug Inlexzo, accusing the company of basing statements on uninterpretable data.Visit original website ↗. |
| EPS Revisions / Estimates | No fresh 7-day consensus EPS revision triggered by Nov 17–20 clinical/MedTech releases; Enterprise Business Review scheduled outside horizon on Dec 8, 2026 jnjJohnson & Johnson Enterprise Business ReviewRegister for Johnson & Johnson's Enterprise Business Review. Tuesday, December 8, 2026. Register and join. Innovating in Health&Care. inside-the-development-of ...Visit original website ↗. | Unavailable near-term estimate revisions are explicitly acknowledged; thesis relies on defensive flow, dividend capture, and mean reversion. |
Investment Thesis
The core investment thesis for buying JNJ now is an asymmetric, low-beta defensive total-return setup over the shortened November 20–27 week, driven by (1) institutional rotation into Healthcare during a bifurcated tech/AI drawdown, (2) four fresh November 17–20 clinical and MedTech execution milestones reinforcing pipeline sentiment, and (3) a confirmed $1.34/share (+0.495%) Q4 ex-dividend on Tuesday, November 24 investor.jnjJohnson & Johnson Announces Quarterly Dividend for Fourth ...Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026 ... The ex-dividend date is November 24, 2026. About Johnson & Johnson.Visit original website ↗ that anchors the highest-probability time-exit branch.
Decider Scenario & Benchmark Comparison (Uncalibrated Analyst Estimates, Referenced to $270.935 at 11:10:00 EST):
- Actual Profit Barrier vs. T1 Reference: The decider's 7-day T1 reference
target_priceis$282.50(+4.27%, November 16 close). Under the execution policy, the actual full-position profit exit is at1.8×T1's percentage return, placing the profit barrier at$291.75(+7.6836%,2.97× ATR14, just above the$290.2552-week high finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗).first_resistance_priceat$275.05(+1.52%, SMA20/VWAP20 confluence) is tracked separately as a path diagnostic. BecauseJNJ's0.20beta makes a+7.68%4-session sprint low-probability, the decider assigns only13.0%probability to the1.8×profit barrier. - Time-Exit Branch (
65.0%probability,+1.65%conditional return): The primary return engine is a controlled rebound above$275.05SMA20/VWAP20 into the November 2710:20:01 ESThorizon, modeled at$274.06ex-dividend price plus the confirmed$1.34dividend ($275.40total value,+1.65%). The dividend is credited once in this guaranteed post-ex-date branch and conservatively omitted from early stop or profit exits. - Stop-Exit Branch (
22.0%probability,-3.59%conditional return): Authored structural stop at$263.50(-2.74%,1.06× ATR14, below the November 19 low of$264.68and SMA50 of$267.33finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗), with conditionalstop_exit_pricemodeled at$261.20(-3.5931%) to account for confirmation delay and macro gap risk. - Net Expected Return & Stress Resilience: After
0.12%estimated friction, the decider's base expected net return is+1.1609%(+0.4609%excess vs. the decider's+0.70%7-daySPYbase estimate; Expected R+0.4230). Deducting the reconciled2.10 ppedge_uncertainty_pct(which covers the2.0306 ppstress minimum) yields-0.9391%conservative absolute return and-1.6391%uncertainty-adjusted excess return—still #1 among all 10 reviewed finalists. In a coherent adverse-market stress (SPY -1.18%),JNJ's stressed return (-0.8697%) still outperformsSPYby+0.3103%.
Risks And Thesis Breakers
- Ex-Dividend Stop Proximity: Tuesday, November 24's mechanical
-$1.34ex-dividend price adjustment narrows the buffer to the$263.50authored stop from$7.435(1.06× ATR14) to$6.095(0.87× ATR14). A weak tape on Monday/Tuesday could pushJNJinto the stop confirmation zone even without fundamental deterioration. - Litigation & Regulatory Headline Overhang: Although Monday November 16's
$5.5Btalc settlement framework was constructive ddnews.gov.iJ&J reaches sweeping talc deal that could end decade ...Johnson & Johnson said on Monday it would pay an estimated $5.5 billion to resolve tens of thousands of lawsuits alleging its baby powder and other talc ...Visit original website ↗, a Louisiana appellate court upheld a multimillion-dollar mesothelioma talc verdict on November 17 businesswireLouisiana Appeals Court Upholds Millions in Damages ...Johnson & Johnson, in which a jury found that talc in its baby powder caused a New Orlean's woman's mesothelioma and death.Visit original website ↗, and on November 19 the FDA issued a marketing rebuke over promotional claims for bladder cancer drug Inlexzo fiercepharmaJ&J draws FDA rebuke over Inlexzo bladder-sparing ...The FDA slammed J&J over misleading claims about its bladder cancer drug Inlexzo, accusing the company of basing statements on uninterpretable data.Visit original website ↗ (accompanied by a routine investor-alert press release morningstarINVESTOR ALERT: Pomerantz Law Firm Investigates ...The investigation concerns whether J&J and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. to ...Visit original website ↗). Fresh adverse court rulings or expanded FDA enforcement would break the defensive-leadership thesis. - Macro Event & Gap Risk: The Wednesday, November 25
8:30 AM ESTdata cluster (Q3 GDP, October PCE/Core PCE, Durable Goods, Jobless Claims) bea.govRelease Schedule | U.S. Bureau of Economic Analysis (BEA)Release Schedule Upcoming Releases Full Schedule 2025 Schedule 2027 Schedule N ews Release D ata Release VVisit original website ↗census.govsourceVisit original website ↗oui.doleta.gOffice of Unemployment InsurancePrior versions of the News Release are available through the application tool below. Publication Schedule: The UI Weekly Claims News Release is published each ...Visit original website ↗ could trigger a broad-market gap below$263.50or a sharp yield spike that pressures dividend equities. - Low-Beta Upside Cap & Intraday VWAP Slip: With
0.20beta finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗ and current trading ($271.075at11:21:00 EST) slightly below session VWAP ($271.638finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗), failure to reclaim$275.05SMA20/VWAP20 would cap gains and leave the position vulnerable to drift. - Model & Calibration Limitations: All scenario probabilities, conditional returns, and benchmark forecasts are uncalibrated analyst estimates rather than empirically fitted frequencies.
JNJ's uncertainty-adjusted excess return (-1.6391%) is negative, reflecting elevated Thanksgiving-week macro dispersion. - Binary-Event & Solvency Status: Zero pending company-specific binary events (earnings, FDA PDUFA, or court rulings) are scheduled inside November 20–27 (Enterprise Business Review is confirmed for December 8, 2026 jnjJohnson & Johnson Enterprise Business ReviewRegister for Johnson & Johnson's Enterprise Business Review. Tuesday, December 8, 2026. Register and join. Innovating in Health&Care. inside-the-development-of ...Visit original website ↗), and no liquidity or solvency risks are present.
- Explicit Thesis Breakers: A sustained breakdown below the November 19 low (
$264.68) and SMA50 ($267.33) that triggers the$263.50stop confirmation, or a material new adverse talc/FDA regulatory development, invalidates the trade.
Investment Recommendation
Buy JNJ (Johnson & Johnson) now for a 1-slot position over the 7-calendar-day horizon (2026-11-20 10:20:01 EST to 2026-11-27 10:20:01 EST), with Medium confidence (descriptive only).
Execution & Stop-Loss Plan (authored_stop_ma60_confirm90_spot_mom15_hard15_confirm10_tp1p8_v2):
- Reference Entry & Fresh Quote: Authored research entry
$270.935(2026-11-20 11:10:00 EST); latest publication check$271.075(2026-11-20 11:21:00 EST,+0.05%drift, support unbroken finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗). - Authored Stop-Loss (
$263.50,-2.74%): Placed below the November 19 low ($264.68) and SMA50 ($267.33). Under the execution policy, a soft stop exit requires the trailing 60-minute average price to remain at or below$263.50for 90 consecutive minutes, with spot still at or below$263.50and a nonpositive 15-minute price change (missing momentum evidence defers the soft exit; recovery checks preserve the confirmation timer until the 60-minute average recovers). - Hard-Loss Backstop & Slippage: A
15%hard-loss condition requires 10 minutes of confirmation. Neither the authored stop nor the hard-loss level guarantees an exact fill across overnight gaps or delayed confirmation; the decider models a conditionalstop_exit_priceof$261.20(-3.59%) before execution friction, with0.10%adverse slippage (0.12%total estimated friction). - Profit Target & Time Exit: Path diagnostic
first_resistance_priceis$275.05(SMA20/VWAP20); strategy-horizon T1 referencetarget_priceis$282.50(+4.27%); the actual full-position profit barrier is$291.75(1.8×T1's percentage return,+7.68%). Any early profit or stop exit leaves proceeds in cash through2026-11-27 10:20:01 EST; otherwise, the position exits at the scheduled horizon on November 27 after capturing the November 24$1.34ex-dividend.
Financial Snapshot
As of Nov 20, 2026 Morning